NASDAQ:IAM Iambic Therapeutics Q3 2026 Earnings Results & Report $11.55 -1.55 (-11.83%) As of 10:44 AM Eastern Iambic Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$6.23 versus the -$0.33 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call8:00 AM ET Iambic Therapeutics EPS ResultsActual EPS-$6.23Consensus EPS -$0.33Beat/MissMissed by -$5.90One Year Ago EPSN/AIambic Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Iambic Therapeutics Q3 2026 Earnings FAQ Did Iambic Therapeutics beat earnings estimates for Q3 2026? Iambic Therapeutics (NASDAQ:IAM) reported earnings of -$6.23 per share for Q3 2026, missing the consensus estimate of -$0.33. The report was announced on Monday, November 16, 2026. Iambic Therapeutics Earnings HeadlinesIambic Provides Business Updates and Third Quarter 2026 Financial Results2 hours ago | globenewswire.comCitigroup Begins Coverage on Iambic Therapeutics (NASDAQ:IAM)November 11, 2026 | americanbankingnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 16 at 1:00 AM | Behind the Markets (Ad)Iambic Therapeutics (NASDAQ:IAM) Stock Picked Up by Analysts at Bank of AmericaNovember 11, 2026 | americanbankingnews.comIambic Therapeutics (NASDAQ:IAM) Stock Picked Up by Analysts at JPMorgan Chase & Co.November 11, 2026 | americanbankingnews.comIambic Shares Rise Ahead Of AI Drug Discovery Panel At Jefferies Healthcare ConferenceNovember 10, 2026 | rttnews.comSee More Iambic Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Iambic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iambic Therapeutics and other key companies, straight to your email. Email Address About Iambic TherapeuticsIambic Therapeutics (NASDAQ:IAM) is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.View Iambic Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.